Drug Profile
Zastaprazan - Onconic Therapeutics
Alternative Names: JP-1366; OCN-101Latest Information Update: 29 Nov 2023
Price :
$50
*
At a glance
- Originator Jeil Pharmaceutical
- Class Antiulcers; Azetidines; Imidazoles; Pyridines; Small molecules
- Mechanism of Action Potassium-competitive acid blockers
-
Orphan Drug Status
Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.
- New Molecular Entity Yes
- Available For Licensing Yes
Highest Development Phases
- Phase III Erosive oesophagitis
- Phase II Gastro-oesophageal reflux
Most Recent Events
- 14 Oct 2023 Efficacy and adverse events data from the phase III Zero-1 trial in Erosive oesophagitis presented at the 31st United European Gastroenterology Week (UEGW-2023)
- 28 Jul 2023 Chemical structure information added
- 07 Feb 2023 Onconic Therapeutics plans a phase I trial to assess food-effects on pharmacokinetics and pharmacodynamics of JP 1366 (In healthy adults) in South Korea in February 2023 (PO, tablet) (NCT05712681)